• Reduced variability in potassium detection from 15% to 1.5% for Biochip
• Transitioning to testing and development using human blood samples
• Engaging with regulatory bodies in H2 2025 and planning clinical trials in 2026

Archer Materials Limited, a semiconductor company advancing quantum technology and medical diagnostics, has built on its previous work on the feasibility of potassium sensing with its Biochip technology and will move towards development and optimization of the device, including the testing of human blood samples. Over the past months, the Archer team has been working to reduce the variability of test results between graphene field effect transistors (gFETs) on the same chip. This has been achieved through the development of Archer's in-house processes during the functionalization to make the gFETs into potassium sensors. This work has led to a significant decrease from 15% to 1.5% in on-chip device variability. By reducing variability to 1.5%, Archer is now able to move to the next stage in the Biochip development and start the testing of human blood samples. This is a major step in moving towards having a working prototype and being ready for clinical trials. In addition to testing human blood, Archer will also continue to work closely with its graphene foundry supplier Paragraf to improve gFET devices to meet the sensing specifications required for the potassium sensor. Engineering plans for 2025 aim to integrate the Biochip into a prototype cartridge system and demonstrate the required potassium sensing accuracy using human blood samples. Preparation for engaging with regulatory bodies will begin soon, and Archer intends to begin these early engagements this year. During 2026, Archer plans to develop the prototype into a manufacturable product and commence clinical trials.

Archer expects to commence clinical trials for potassium detection using the Biochip in 2026, subject to regulatory feedback. The company is also preparing to engage with regulatory bodies in the second half of 2025.